United Capital Financial Advisers, LLC Viracta Therapeutics, Inc. Transaction History
United Capital Financial Advisers, LLC
- $11.7 Billion
- Q4 2024
A detailed history of United Capital Financial Advisers, LLC transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, United Capital Financial Advisers, LLC holds 42,995 shares of VIRX stock, worth $1,289. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,995
Previous 42,995
-0.0%
Holding current value
$1,289
Previous $9,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VIRX
# of Institutions
37Shares Held
3.66MCall Options Held
1.8KPut Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.63MShares$48,7870.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA289KShares$8,6750.0% of portfolio
-
Aisling Capital Management LP New York, NY289KShares$8,6570.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny286KShares$8,5910.0% of portfolio
-
Black Rock Inc. New York, NY273KShares$8,1980.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $1.13M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...